For example, in patients with Her2-positive breast cancer BMs (10, 11), those with ALK-rearranged (12, 13) or EGFR-mutated (14, 15) NSCLC BMs, and for BRAF V600 E mutated melanoma BMs (16), targeted therapies with significant intracranial activity are available. This evidence concerns the gene EGFR and breast carcinoma.